TransMedics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1998-08-01
- Employees
- 584
- Market Cap
- -
- Website
- www.transmedics.com
- Introduction
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
GLP-1 Agonists Show Significant Benefits for Kidney Transplant Recipients with Type 2 Diabetes
• A landmark study by NYU Langone Health reveals kidney transplant recipients with type 2 diabetes who take GLP-1 agonists experience 49% lower risk of organ failure and 31% reduced mortality within five years.
• While the anti-obesity medications demonstrated substantial benefits, researchers observed a 49% increased risk of diabetic retinopathy, highlighting the need for careful eye health monitoring in these patients.
• The comprehensive analysis of 18,016 kidney transplant recipients provides the strongest evidence to date supporting GLP-1 agonists as safe and effective tools for managing diabetes in transplant patients.
Phase III LEAP-012 Study Shows Promising Results for Intermediate-Stage HCC Treatment
The LEAP-012 phase III trial demonstrates that combining lenvatinib, pembrolizumab, and TACE significantly improves progression-free survival in patients with intermediate-stage hepatocellular carcinoma, compared to placebo plus TACE.
© Copyright 2025. All Rights Reserved by MedPath